Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 114-121

  Clausi, Amber L ^a   Morin, Andrea ^a   Carpenter, John F ^b   Randolph, Theodore W ^a  

^a University of Colorado at Boulder   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adjuvant; Alkaline phosphatase; Aluminum hydroxide; Immune response; Particle size distribution; Protein conformation

Indexed keywords

ADJUVANT; ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G1 ANTIBODY; VACCINE;

ANIMAL EXPERIMENT; ANTIGEN STRUCTURE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVITY; FEMALE; FREEZE DRYING; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RODENT; SPRAY DRYING; TEMPERATURE;

EID: 58149267690     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21433     Document Type: Article

References (26)

1. Singh M, O'Hagan D. 1999. Advances in vaccine adjuvants. Nat Biotechnol 17:1075-1081.
2. O'Hagan DT, MacKichan ML, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18:69-85.
3. Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. 1990. Aluminum compounds used as adjuvants in vaccines. Pharm Res 7:1282-1288.
4. Johnston CT, Wang SL, Hem SL. 2002. Measuring the surface area of aluminum hydroxide adjuvant. J Pharm Sci 91:1702-1706.
5. Romero Mendez IZ, Shi Y, Hogenesch H, Hem SL. 2006. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine.
6. Lindblad EB. 2004. Aluminium compounds for use in vaccines. Immunol Cell Biol 82:497-505.
7. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines-Current status, problems and future-prospects. Vaccine 13:1263-1276.
8. Gupta RK, Rost BE. 2000. Aluminum compounds as vaccine adjuvants. In: O'Hagan D, editor. Vaccine adjuvants: Preparation methods and research protocols. Totowa, NJ: Humana Press Inc. pp. 65-89.
9. Cox JC, Coulter AR. 1997. Adjuvants-A classification and review of their modes of action. Vaccine 15: 248-256.
10. Callahan PM, Shorter AL, Hem SL.1991. The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm Res 8:851-858.
11. Grun JL, Maurer PH. 1989. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121:134-145.
12. Hogen Esch H. 2002. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20:S34-S39.
13. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. 2005. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 280:13406-13414.
14. Thai R, Moine G, Desmadril M, Servent D, Tarride JL, Menez A, Leonetti M. 2004. Antigen stability controls antigen presentation. J Biol Chem 279: 50257-50266.
15. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14:969-975.
16. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. 2001. Factors affecting short-term and longterm stabilities of proteins. Adv Drug Deliv Rev 46:307-326.
17. Webb SD, Golledge SL, Cleland JL, Carpenter JF, Randolph TW. 2002. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations. J Pharm Sci 91: 1474-1487.
18. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res 18:1345-1353.
19. Diminsky D, Moav N, Gorecki M, Barenholz Y. 1999. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18:3-17.
20. Maa YF, Zhao L, Payne LG, Chen D. 2003. Stabilization of alum-adjuvanted vaccine dry powder formulations: Mechanism and application. J Pharm Sci 92:319-332.
21. Nygaard UC, Samuelsen M, Aase A, Lovik M. 2004. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. Toxicol Sci 82:515-524.
22. Clausi AL, Merkley SA, Carpenter JF, Randolph TW. 2008. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci 97:2049-2061.
23. Miller DP, de Pablo JJ, Corti H. 1997. Thermophysical properties of trehalose and its concentrated aqueous solutions. Pharm Res 14:578-590.
24. Luthra S, Obert JP, Kalonia DS, Pikal MJ. 2007. Investigation of drying stresses on proteins during lyophilization: Differentiation between primary and secondary-drying stresses on lactate dehydrogenase using a humidity controlled mini freeze-dryer. J Pharm Sci 96:61-70.
25. Hem SL, White JL. 1984. Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. J Parenter Sci Technol 38:2-10.
26. Clausi A, Cummiskey J, Merkley S, Carpenter JF, Randolph T. 2008. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci published online April 8, DOI: 10.1002/jps.21390.